Sarah Ferber biography
Prof. Sarah Ferber Ph.D. serves as Chief Scientific Officer of the Company. Prof. Ferber has served as the Company's Chief Scientific Officer since her appointment on February 2, 2012. Since 2017, Prof. Ferber has been the Principal Investigator of cell therapy for TMU DiaCure. Prof. Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. Most of the research was conducted in Prof. Ferber's Endocrine Research Lab. Prof. Ferber received Teva, Lindner, Rubin and Wolfson awards for this research. Prof. Ferber's research work has been funded over the past 15 years by the JDRF, the Israel Academy of Science foundation (ISF), BIODISC and DCure. Prof. Ferber earned her B.Sc. from Technion-Haifa, a M.Sc. in Biochemistry from Technion-Haifa and a Ph.D. in Medical Sciences from Technion-Haifa. She also holds a Post Doctorate degree in Molecular Biology from Harvard Medical School and a degree in Cell Therapy Sciences from UTSW, Dallas.
What is the salary of Sarah Ferber?
As the Chief Scientific Officer of Orgenesis Inc, the total compensation of Sarah Ferber at Orgenesis Inc is $268,783. There are 5 executives at Orgenesis Inc getting paid more, with Vered Caplan having the highest compensation of $1,577,660.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Sarah Ferber?
Sarah Ferber is 65, he's been the Chief Scientific Officer of Orgenesis Inc since 2012. There are 1 older and 11 younger executives at Orgenesis Inc. The oldest executive at Orgenesis Inc is Prof. Sarah Ferber Ph.D., 67, who is the Founder & Chief Scientific Officer.
What's Sarah Ferber's mailing address?
Sarah's mailing address filed with the SEC is C/O ORGENESIS INC., 20271, GOLDENROD LANE, GERMANTOWN, MD, 20876.
Insiders trading at Orgenesis Inc
Over the last 12 years, insiders at Orgenesis Inc have traded over $4,872,134 worth of Orgenesis Inc stock and bought 375,420 units worth $216,187 . The most active insiders traders include Sca Theodorus, Ii Sa Theodorus e Olivier Belenger. On average, Orgenesis Inc executives and independent directors trade stock every 263 days with the average trade being worth of $1,118,704. The most recent stock trade was executed by Victor Miller on 1 April 2024, trading 25,000 units of ORGS stock currently worth $12,500.
What does Orgenesis Inc do?
orgenesis inc (orgs) is a medical device company located in 21 sparrow cir, white plains, new york, united states.
What does Orgenesis Inc's logo look like?
Orgenesis Inc executives and stock owners
Orgenesis Inc executives and other stock owners filed with the SEC include:
-
Vered Caplan,
Chairperson of the Board of Directors, Chief Executive Officer -
Vered Caplan M.Sc.,
Chairperson of the Board, CEO & Pres -
Darren Head,
Chief Executive Officer of Masthercell Global -
Neil T. Reithinger CPA,
CFO, Sec. & Treasurer -
Denis Bedoret,
President of Masthercell Global -
Sarah Ferber,
Chief Scientific Officer -
Neil Reithinger,
Chief Financial Officer, Treasurer, Secretary -
David Sidransky,
Independent Director -
Guy Yachin,
Independent Director -
Yaron Adler,
Independent Director -
Ashish Nanda,
Independent Director -
Mario Philips,
Independent Director -
Vincent Vandamme,
Sr. VP of Quality Strategy -
Lilach Harel,
VP of Global HR -
Osher Partok Rheinisch,
Gen. Counsel & Compliance Officer -
Dr. Shimon Hassin Ph.D.,
Chief Technology Officer -
Joseph Green,
Chief Operating Officer -
Evan Fishman,
Chief Financial Officer -
Prof. Sarah Ferber Ph.D.,
Founder & Chief Scientific Officer -
Elliot Maltz,
Chief Financial Officer -
Olivier Belenger,
-
Hugues Bultot,
Director -
Libre De Bruxelles Universite,
-
Ii Sa Theodorus,
-
Sca Theodorus,
-
Etti Hanochi,
Director -
Itzhak Vider,
Director -
Victor Miller,
CHIEF FINANCIAL OFFICER -
Jacob Safier,
10% owner -
Mark Goodman,
Director -
Kunik Efrat Assa,
Chief Development Officer